Prof. Huawei Yang 杨华伟
Chief Physician, Professor
Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast diseases, breast plastic surgery, sentinel lymph node biopsy, minimally invasive surgery, neoadjuvant and endocrine therapy, and breast reconstruction.
Dr. Yang holds a medical doctorate and graduated from Central South University Xiangya School of Medicine in 1997, with training at the University of Minnesota. As Director of Ward 1, Breast Surgery, the doctor focuses on clinical care and research for breast cancer, including reconstruction techniques. Dr. Yang has led National Natural Science Foundation projects and published 40 academic papers.
Professional roles
- Standing Committee Member, Oncologic Plastic Surgery Branch, China Anti-Cancer Association
- Standing Committee Member, Tumor Reconstruction Branch, Chinese Association of Plastics and Aesthetics
- Vice Chair, Breast Cancer Professional Committee, Guangxi Anti-Cancer Association
- Vice Chair, Breast Disease Professional Committee, Guangxi Medical Doctor Association
Name order: in Chinese the family name comes first (Yang Huawei). Papers usually list the name as Huawei Yang or Yang H.
Selected publications
28 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Cancer Res, 2026 (senior author): Expression, prognostic association, and immune microenvironment correlates of C4orf50 in breast cancer: a The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) bioinformatics study. PubMed 42870827
- Front Oncol, 2026 (senior author): Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. PubMed 42851451
- Front Oncol, 2026 (senior author): A machine learning-based prognostic model for de novo metastatic HR-positive breast cancer: SEER cohort with external validation. PubMed 42539395
- Biochim Biophys Acta Mol Cell Res, 2026 (senior author): TMEM132A affects proliferation, invasion, and apoptosis via the β-catenin-dependent Wnt signaling in breast cancer. PubMed 42203132
- Dig Liver Dis, 2026 (senior author): Development and external validation of a machine learning model for predicting in-hospital mortality in acute liver failure. PubMed 41692645
- Front Immunol, 2026 (senior author): Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence. PubMed 41737214
- Discov Oncol, 2026 (senior author): Omics analysis reveals the prognostic value of IPCDS models and potential targets for immunotherapy. PubMed 41591651
- NPJ Precis Oncol, 2026 (senior author): Integrative multi-omics and machine learning framework identifies PRDX4 as a redox-EMT regulator and predictive marker in bone-metastatic breast cancer. PubMed 41571856
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion